Your session is about to expire
← Back to Search
Glucagon-like peptide-1 (GLP-1) receptor agonist
Efinopegdutide 20 mg/mL for Non-alcoholic Fatty Liver Disease
Phase 2
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to ~29 weeks
Awards & highlights
Study Summary
This trial is testing if efinopegdutide is better than semaglutide at reducing liver fat content in people with NAFLD.
Eligible Conditions
- Non-alcoholic Fatty Liver Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to ~29 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to ~29 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks
Percentage of Participants Who Discontinued Study Intervention Due to an AE
Percentage of Participants Who Experienced an Adverse Event (AE)
Secondary outcome measures
Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks
Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks
Mean Percent Change From Baseline in Body Weight After 24 Weeks
+5 moreSide effects data
From 2022 Phase 2 trial • 145 Patients • NCT0494499228%
Nausea
17%
Constipation
17%
Diarrhoea
17%
Vomiting
17%
Decreased appetite
13%
Abdominal pain
11%
COVID-19
10%
Abdominal pain upper
8%
Dyspepsia
8%
Gastrooesophageal reflux disease
7%
Headache
6%
Abdominal distension
6%
Flatulence
6%
Urinary tract infection
6%
Alanine aminotransferase increased
6%
Lipase increased
6%
Dizziness
1%
Calculus urinary
1%
Fatigue
100%
80%
60%
40%
20%
0%
Study treatment Arm
Efinopegdutide
Semaglutide
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: EfinopegdutideExperimental Treatment1 Intervention
Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
Group II: SemaglutideActive Control1 Intervention
Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Efinopegdutide 20 mg/mL
2021
Completed Phase 2
~150
Find a Location
Who is running the clinical trial?
Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,581,677 Total Patients Enrolled
3 Trials studying Non-alcoholic Fatty Liver Disease
228 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Merck Sharp & Dohme LLCLead Sponsor
3,886 Previous Clinical Trials
5,054,426 Total Patients Enrolled
7 Trials studying Non-alcoholic Fatty Liver Disease
673 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,777 Previous Clinical Trials
8,063,335 Total Patients Enrolled
4 Trials studying Non-alcoholic Fatty Liver Disease
361 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger